IngredientesN-Acetyl-Tirosina (NALT) es una forma modificada del aminoácido L-tirosina, producida al unir un grupo acetilo para mejorar su estabilidad y solubilidad en agua. La tirosina es un aminoácido no esencial sintetizado en el cuerpo a partir de fenilalanina y es un precursor de varios neurotransmisores y hormonas crÃticos, incluyendo dopamina, norepinefrina, epinefrina y hormonas tiroideas (T3 y T4).
Como suplemento, la N-acetil-tirosina se utiliza para apoyar el estado de alerta mental, la resiliencia al estrés, el enfoque y el rendimiento cognitivo, particularmente durante perÃodos de estrés agudo, fatiga o privación del sueño. Se incluye comúnmente en formulaciones nootrópicas, mezclas pre-entrenamiento y combinaciones adaptogénicas debido a su papel en la producción de catecolaminas. La acetilación de la tirosina puede mejorar su absorción y biodisponibilidad en comparación con la L-tirosina estándar, aunque los hallazgos cientÃficos al respecto son mixtos.
NALT es especialmente reconocida por sus efectos en situaciones donde ocurre el agotamiento de neurotransmisores debido al estrés, el ejercicio intenso o la sobrecarga cognitiva. Ayuda a restaurar la sÃntesis de dopamina y norepinefrina, mejorando el estado de ánimo, la motivación y la función ejecutiva. También puede ser beneficiosa para apoyar la función tiroidea, particularmente en individuos con hipotiroidismo subclÃnico o bajo estrés crónico, donde la disponibilidad de tirosina puede influir en la sÃntesis de hormonas tiroideas.
Adicionalmente, algunas investigaciones sugieren que la suplementación con tirosina (incluyendo NALT) puede mejorar el rendimiento cognitivo en entornos exigentes como operaciones militares o entornos profesionales de alta presión. No actúa como estimulante, sino que proporciona apoyo fundamental para la producción de neurotransmisores.
Uso Histórico
N-Acetil-Tirosina es un derivado moderno de la L-tirosina y no aparece en el registro histórico de la medicina herbal o tradicional. Sin embargo, su compuesto original—la tirosina—fue descubierta por primera vez en 1846 en la caseÃna (una proteÃna de la leche) y nombrada a partir de la palabra griega para queso, tyros. La importancia biológica de la tirosina se hizo más clara con el desarrollo de la investigación bioquÃmica y neuroquÃmica en el siglo XX.
El uso de alimentos ricos en tirosina para la resiliencia mental y fÃsica sà tiene raÃces en prácticas tradicionales. Alimentos ricos en proteÃnas como la carne, los lácteos, las legumbres y las semillas—fuentes naturales de tirosina—han sido recomendados durante mucho tiempo en sistemas tradicionales como el Ayurveda y la Medicina Tradicional China (TCM) para nutrir el cerebro, mejorar la fuerza y estabilizar el estado de ánimo. Aunque carecÃan de la comprensión molecular, los practicantes antiguos frecuentemente recomendaban dichos alimentos durante perÃodos de convalecencia, estrés emocional o fatiga mental.
El uso especÃfico de la N-acetil-tirosina como suplemento comenzó a finales del siglo XX, particularmente entre biohackers, atletas y quienes buscaban una función cognitiva mejorada bajo presión. Su inclusión en productos pre-entrenamiento y de mejora neurológica ha crecido debido a su capacidad para apoyar la reposición de neurotransmisores sin sobreestimular directamente el sistema nervioso central.
Hoy en dÃa, NALT es reconocida como un nutriente de apoyo para la sÃntesis de neurotransmisores, la resistencia cognitiva y la recuperación del estrés, especialmente en entornos fÃsicos y mentales de alta demanda.
Condiciones de salud que coenzima Q10 (CoQ10) puede ayudar a apoyar.
CoQ10 is an antioxidant and mitochondrial cofactor studied in ALS because of mitochondrial dysfunction and oxidative stress in disease pathology. In SOD1 transgenic mice, CoQ10 extended survival by 6 days. A Phase II multi-center RCT (n=185) testing doses of 1,800–2,700 mg/day found CoQ10 did not improve ALSFRS-R decline sufficiently to justify a Phase III trial.
CoQ10 plays a critical role in mitochondrial energy production, and its myocardial deficiency is implicated in ischemic heart disease. A 1985 double-blind, placebo-controlled crossover RCT in 12 stable angina patients showed 150 mg/day for 4 weeks significantly increased exercise time (345 to 406 s, p<0.05) and delayed ST-segment depression onset (196 to 284 s, p<0.01). The Linus Pauling Institute lists CoQ10 as potentially improving exercise tolerance and reducing ischemia signs in stable angina.
CoQ10 is a well-established endogenous antioxidant that functions within cell membranes and mitochondria to scavenge reactive oxygen species, protect lipids and proteins from oxidative damage, and upregulate antioxidant enzyme activity. Multiple meta-analyses of randomized controlled trials (RCTs) confirm that CoQ10 supplementation significantly reduces the oxidative stress biomarker malondialdehyde (MDA) and increases total antioxidant capacity (TAC) and superoxide dismutase (SOD) activity in human subjects. The evidence base is clinical and mechanistic, spanning diverse patient populations.
CoQ10 reduces oxidative stress on LDL and supports mitochondrial function in endothelial cells. RCTs combining CoQ10 with AGE showed significant PWV reduction (mean −1.21 m/s). Meta-analyses show CoQ10 may reduce all-cause mortality in heart failure and restore endothelial function in patients on statin therapy, which depletes endogenous CoQ10.
CoQ10 is an endogenous mitochondrial electron carrier proposed to enhance aerobic energy production and reduce exercise-induced oxidative stress. The NIH ODS exercise fact sheet directly addresses CoQ10, finding limited ergogenic benefit and noting one study where CoQ10 groups had smaller power improvements than placebo, suggesting potential interference with training adaptation.
Coenzyme Q10 has been evaluated in multiple meta-analyses of RCTs for blood pressure reduction. A meta-analysis of 12 RCTs found CoQ10 reduced SBP by up to 17 mmHg and DBP by up to 10 mmHg in hypertensive patients. Mechanisms involve antioxidant activity, endothelial function improvement, and enhanced nitric oxide bioavailability.
Multiple RCTs and meta-analyses show CoQ10 supplementation modestly reduces fasting blood glucose and HbA1c, particularly in patients with type 2 diabetes. A 2022 GRADE-assessed meta-analysis of 40 RCTs concluded that 100–200 mg/day provides the greatest glycemic benefit. Results remain somewhat heterogeneous across trials. The primary mechanism is reduction of mitochondrial oxidative stress in pancreatic beta cells and peripheral tissues.
CoQ10 is an essential mitochondrial cofactor that supports ATP production in brain cells, which consume approximately 20% of the body's energy. It also acts as a neuroprotective antioxidant. A meta-analysis found moderate evidence that CoQ10 supplementation (100–400 mg/day) improves general cognitive performance in older adults, and low CoQ10 is associated with cognitive decline and reduced antioxidant defenses.
CoQ10 is an essential mitochondrial electron transport chain component. A 2022 systematic review and meta-analysis of 13 RCTs (n=1,126) found CoQ10 supplementation produced a statistically significant reduction in fatigue scores vs. placebo (Hedges' g=−0.398, p=0.001). Higher daily doses and longer treatment correlated with greater fatigue reduction. Burnout involves genuine mitochondrial stress, making CoQ10 a mechanistically rationale supplement for recovery.
CoQ10 is an essential electron carrier in the mitochondrial electron transport chain, directly facilitating ATP synthesis. Clinical and in vitro studies confirm its role in improving mitochondrial respiration, transmembrane potential, and ATP output. Levels decline with age and statin use, making supplementation broadly relevant to cellular energy support.
CoQ10 is primarily relevant to cholesterol management as an adjunct to statin therapy: statins deplete CoQ10 by up to 40%, and supplementation addresses this deficiency. CoQ10 inhibits LDL oxidation and is included in authoritative cholesterol supplement reviews.
Multiple RCTs demonstrate that CoQ10 supplementation (alone or with NADH) significantly reduces fatigue in chronic fatigue syndrome (ME/CFS) patients. A 2021 RCT of 242 ME/CFS patients showed improved fatigue perception, sleep quality, and health-related quality of life over 12 weeks. CoQ10 deficiency is well-documented in CFS and is mechanistically linked to impaired mitochondrial ATP production.
Multiple randomized controlled trials and meta-analyses provide clinical evidence that CoQ10 supplementation significantly reduces key markers of chronic inflammation, including CRP, TNF-α, and IL-6. The primary mechanism involves CoQ10's inhibition of NF-κB-mediated pro-inflammatory gene expression, coupled with its antioxidant activity in the mitochondrial electron transport chain. Results are broadly positive but some heterogeneity exists across trials, and larger studies are still warranted.
Coenzyme Q10 (CoQ10) supplementation has shown efficacy in migraine prevention and fibromyalgia-related chronic pain in multiple clinical trials, including RCTs. It reduces mitochondrial oxidative stress and inflammation. At 150–300 mg/day, it decreases migraine frequency, headache days, and nausea.
CoQ10 (ubiquinone/ubiquinol) supports circulation by improving endothelial function via enhanced nitric oxide bioavailability, reducing oxidative stress in arterial walls, improving vascular tone, and supporting cardiac output in heart failure. Meta-analyses confirm modest blood pressure reductions and improvements in endothelial function. Its levels decline with age and with statin use, making supplementation particularly relevant in cardiovascular populations.
CoQ10 has been investigated in human clinical trials for its potential to support cognitive function and counteract age-related cognitive decline, primarily through its roles as a mitochondrial antioxidant and ATP-production facilitator. Endogenous CoQ10 levels decline with age, and low plasma CoQ10 has been associated with poorer cognitive and executive function in older adults. A 2025 review of 8 human RCTs found mixed results: roughly half showed benefit on cognition while the other half reported no significant improvement. Current evidence is preliminary and insufficient to support CoQ10 as a standard anti-cognitive-decline therapy.
CoQ10 (coenzyme Q10) is a critical mitochondrial electron transport chain component and antioxidant depleted in states of oxidative stress, including post-concussion. Animal TBI studies show CoQ10 administration decreases TBI biomarkers, neuronal loss, and mitochondrial damage. A 2024 meta-analysis (2000–2023 literature) identified CoQ10 as among the nutraceuticals showing promise for TBI management alongside creatine and magnesium. Multiple peer-reviewed reviews support its theoretical and preclinical rationale for concussion recovery.
CoQ10 (ubiquinone) inhibits tyrosinase activity and suppresses MITF-mediated melanin synthesis, making it relevant for pigmentary dark circles. It was included as an active ingredient in a 2025 open-label clinical study (PMC12235579) that achieved a 47.94% reduction in periorbital hyperpigmentation over 6 weeks. A randomized double-blind placebo-controlled study on under-eye dark circles also incorporated CoQ10 as a key active.
CoQ10 (ubiquinone) has been studied as an adjunct for depression, particularly in patients with mitochondrial dysfunction and treatment-resistant depression. A 2021 PMC review identified CoQ10 among agents with evidence for improving depressive symptoms. It reduces oxidative stress, supports mitochondrial energy production, and modulates monoamine levels.
CoQ10 has been studied for dry eye disease through clinical trials showing topical CoQ10 with crosslinked hyaluronic acid improved DED outcomes, reduced all cytokine levels, and elevated total antioxidant status. Histopathological analyses confirmed CoQ10 protects lacrimal gland structure and function from oxidative damage. It is one of ten evidence-supported DED nutrients per a 2024 Frontiers in Pharmacology systematic review.
CoQ10 is an essential component of the mitochondrial electron transport chain and a lipid-soluble antioxidant. A systematic review and meta-analysis of 13 RCTs (n=1,126) found CoQ10 supplementation significantly reduced fatigue scores versus placebo. It is especially relevant for populations with low CoQ10 levels, including older adults and those with chronic fatigue syndrome.
CoQ10 has preclinical and mechanistic evidence supporting its use as adjunctive therapy in epilepsy. Animal studies show CoQ10 reduces seizure severity in PTZ and pilocarpine models, augments the effects of antiepileptic drugs like phenytoin and valproate, and protects against seizure-induced oxidative damage and neuronal loss. CoQ10 deficiency is linked to epileptic manifestations.
CoQ10 is concentrated in sperm mitochondria and acts as both an energy promoter and antioxidant for flagellar movement. Multiple RCTs and a 2025 systematic review and meta-analysis found CoQ10 supplementation significantly increases total sperm count, total and progressive motility, and normal morphology while raising serum testosterone and inhibin B. Standard clinical doses are 100–300 mg/day for 3–6 months.
Multiple RCTs and meta-analyses show CoQ10 supplementation increases clinical pregnancy rates in infertile women undergoing ART, with one meta-analysis (5 RCTs) reporting 28.8% vs. 14.1% clinical pregnancy rate vs. placebo (OR 2.44, 95% CI 1.30–4.59). It reduces reactive oxygen species in oocytes and supports mitochondrial energy production. Evidence is strongest in women with diminished ovarian reserve or poor ovarian response.
CoQ10 deficiency and mitochondrial dysfunction have been documented in FM patients, with tissue CoQ10 levels reportedly 40–50% below normal. A randomized double-blind placebo-controlled trial in 20 FM patients found 300 mg/day CoQ10 for 40 days significantly reduced FIQ scores, pain, fatigue, and tender points versus placebo. A separate randomized crossover study in 22 female FM patients showed CoQ10 improved pain-related outcomes by 24–37% and reduced sleep disturbance by ~33%.
CoQ10 has been investigated for glaucoma neuroprotection based on its mitochondrial bioenergetic and antioxidant functions. Preclinical studies in rodent models of ocular hypertension showed significant neuroprotection of RGCs. Clinical studies demonstrated that topical CoQ10 combined with vitamin E improved PERG amplitudes in POAG patients.
CoQ10 has been evaluated in multiple RCTs as an adjunct to scaling and root planing for periodontitis. A 2025 systematic review and meta-analysis of 10 RCTs found that oral supplementation at 120 mg/day resulted in significantly greater mean reductions in probing pocket depth (0.41 mm) and clinical attachment level gain (0.52 mm) vs. controls. Locally delivered CoQ10 gel also reduces gum bleeding.
Coenzyme Q10 (ubiquinone) has Level C evidence (possibly effective) for migraine prevention per AAN/AHS guidelines. An RCT by Sándor et al. (2005, n=42) showed 300 mg/day reduced migraine frequency by 50% in 47.6% of patients vs. 14.4% on placebo. Mitochondrial dysfunction is implicated in migraine pathophysiology and CoQ10 supports mitochondrial energy production.
CoQ10 is an endogenous mitochondrial coenzyme whose levels decline significantly with age, reducing cellular energy production and antioxidant defense. Clinical research links CoQ10 supplementation to improved mitochondrial function, cardiovascular health, and reduced oxidative stress markers. A Frontiers in Physiology review summarizes its role in aging and age-related disease.
Coenzyme Q10 (CoQ10) supports mitochondrial energy production and acts as a powerful antioxidant in cochlear cells. A 2025 double-blind RCT (n=50) found 100 mg/day of CoQ10 significantly decreased tinnitus disability and loudness in presbycusis patients over 6 weeks. A 2007 clinical trial showed benefit for tinnitus patients with low CoQ10 blood levels. A 2026 systematic scoping review identified 14 studies linking CoQ10 to hearing outcomes.
CoQ10 has substantial clinical evidence supporting its role in heart health, particularly in heart failure (HF). As an essential cofactor for mitochondrial ATP production and a potent antioxidant, CoQ10 levels are measurably depleted in HF patients and correlate inversely with disease severity. The landmark Q-SYMBIO randomized controlled trial demonstrated significant reductions in cardiovascular mortality and major adverse cardiac events with supplementation. Evidence also supports benefits in endothelial function, vascular stiffness, and oxidative stress across broader cardiovascular disease contexts.
CoQ10 is a mitochondrial electron carrier reduced in heart disease; its depletion is linked to arrhythmia risk. A meta-analysis of 8 RCTs found cardiac surgery patients treated with CoQ10 were significantly less likely to develop ventricular arrhythmias (OR 0.05, 95% CI 0.01–0.31). Proposed mechanisms include improved cellular energy production, membrane stabilization, and reduced ischemia-induced arrhythmogenesis.
Clinical RCTs demonstrate that CoQ10 supplementation reduces HOMA-IR, a validated index of insulin resistance, in both prediabetic and type 2 diabetic populations. A randomized double-blind placebo-controlled trial of 80 patients with impaired glucose tolerance showed significant HOMA-IR reduction after 8 weeks of CoQ10. The mechanism involves reduced oxidative stress restoring mitochondrial efficiency in insulin-sensitive tissues.
Coenzyme Q10 (ubiquinol/ubiquinone) is an endogenous mitochondrial antioxidant with documented benefits in CKD, where CoQ10 deficiency has been observed. Clinical studies in CKD and hemodialysis patients show CoQ10 supplementation reduces oxidative stress markers, improves mitochondrial function in renal tubular cells, and some trials show modest improvements in creatinine clearance and GFR.
CoQ10 is naturally concentrated in the liver, where it supports mitochondrial energy production and acts as a lipid-soluble antioxidant. Systematic reviews and meta-analyses of RCTs indicate CoQ10 supplementation modestly reduces liver enzymes (ALT and AST) in NAFLD patients. Evidence for broader 'detoxification' is limited to hepatoprotective effects against drug-induced and metabolic liver injury.
CoQ10 is a mitochondrial antioxidant cofactor found in the electron transport chain. A clinical study (Feher 2005) demonstrated that a combination of CoQ10, acetyl-L-carnitine, and omega-3 fatty acids stabilized visual functions in early AMD patients by improving mitochondrial function in the RPE. Reviews of AMD antioxidants consistently identify CoQ10 as effective in improving visual function in early AMD. Typical dose in AMD studies: 50–100 mg/day.
CoQ10 (ubiquinone) is a vital component of the mitochondrial electron transport chain and a potent antioxidant. Clinical studies show CoQ10 supplementation reduces fatigue and may support mental energy, particularly in individuals with CoQ10 deficiency or older adults with declining mitochondrial function.
Multiple randomized controlled trials (RCTs) and meta-analyses demonstrate that CoQ10 supplementation can beneficially modulate key features of metabolic syndrome (MetS), including oxidative stress, inflammation, insulin resistance, and adipokine dysregulation. A 2020 PMC meta-analysis of RCTs (318 participants) found CoQ10 significantly increased adiponectin and lowered inflammation markers in MetS patients. However, effects on individual components such as dyslipidemia, hypertension, and glycemia are inconsistent across trials, and at least one RCT found no significant benefit of CoQ10 alone on MetS components.
CoQ10 is a biochemically essential component of the mitochondrial electron transport chain, directly enabling cellular ATP synthesis via oxidative phosphorylation — making it a foundational element of metabolic energy production. Beyond this core bioenergetic role, CoQ10 participates in fatty acid β-oxidation, pyrimidine biosynthesis, and gene expression related to cellular metabolism. Clinical trials and meta-analyses document measurable improvements in glycemic markers (fasting glucose, HbA1c, HOMA-IR) in individuals with type 2 diabetes or metabolic syndrome, particularly at doses of 100–200 mg/day. Evidence for broader metabolic benefits (e.g., lipid profiles, oxidative stress reduction) is supported by multiple RCTs, though effect sizes are generally modest.
CoQ10 is supported by Level C evidence (possibly effective) per AAN/AHS guidelines for migraine prevention. A 2024 meta-analysis of RCTs found CoQ10 decreased migraine frequency (MD = −1.73), severity (MD = −1.35), and duration (MD = −1.72). It is well tolerated with few adverse events.
CoQ10 is an essential electron carrier in the mitochondrial respiratory chain and a key component of the inner mitochondrial membrane. Deficiency is directly linked to mitochondrial disease phenotypes including encephalomyopathy and myopathy. Clinical supplementation evidence shows improvements in mitochondrial bioenergetics, physical performance, and quality of life, particularly in aging and primary CoQ10 deficiency syndromes.
CoQ10 is an endogenous mitochondrial electron carrier and lipid-soluble antioxidant. A 2022 PMC systematic review concluded CoQ10 supplementation may offer a favorable profile in controlling oxidative patterns with anti-inflammatory activity at the cellular level in response to exercise, functioning as a protective and recuperative substance.
The most robust clinical evidence concerns statin-associated muscle symptoms (SAMS). Multiple meta-analyses of RCTs show CoQ10 supplementation significantly reduces muscle pain, weakness, cramps, and tiredness in statin-treated patients, though some analyses are discordant. CoQ10 is proposed to restore muscle mitochondrial function depleted by statin-induced CoQ10 reduction.
CoQ10 is an endogenous mitochondrial electron carrier essential for neuronal energy production. It has been clinically studied for neuroprotective effects in Parkinson's disease, migraine prevention, and protection against oxidative stress-mediated neurodegeneration.
Coenzyme Q10 is an endogenous mitochondrial electron carrier essential for ATP synthesis in metabolically demanding nerve cells. Mitochondrial dysfunction is a recognized mechanism in peripheral neuropathy, and CoQ10 supports nerve cell energy production. It is listed in authoritative neuropathy databases and is particularly relevant in statin-associated neuropathy (statins deplete CoQ10) and chemotherapy-induced peripheral neuropathy.
CoQ10 supports nitric oxide (NO) bioavailability by protecting endothelial NO synthase (eNOS) from oxidative inactivation and reducing superoxide-mediated NO degradation. Clinical trials in type 2 diabetes and coronary artery disease patients show improved endothelium-dependent vasodilation (flow-mediated dilation) with CoQ10 supplementation. Evidence from NIH StatPearls lists improving endothelial function as a Level 2 clinical indication.
CoQ10 has been extensively studied in Parkinson's disease based on evidence of mitochondrial Complex I deficiency in PD patients. Phase II trials showed dose-dependent slowing of functional decline; however, a large Phase III RCT (QE3) failed to confirm disease-modifying benefit. Meta-analyses show it is safe but does not significantly improve motor UPDRS scores versus placebo.
CoQ10 is an endogenous antioxidant that has been shown effective for PCOS women undergoing assisted reproductive technologies, reducing insulin resistance, increasing FSH, and improving blood lipids. A meta-analysis confirmed CoQ10 reduces fasting plasma glucose and HOMA-IR and improves sex hormone levels in PCOS.
CoQ10 (ubiquinone/ubiquinol) is essential for mitochondrial electron transport chain function and ATP synthesis, making it directly relevant to physical endurance. A 2022 PMC review of combined CoQ10 supplementation trials found favorable outcomes on physical performance parameters. It has been identified as an IOC-relevant supplement for endurance athletes, and RCTs have shown it supports exercise tolerance and reduces exercise-induced oxidative stress.
CoQ10 is essential for mitochondrial electron transport and ATP production, and its levels are depleted during illness and critical disease states. Post-operative and post-illness recovery protocols specifically include CoQ10 to restore mitochondrial energy production, reduce oxidative stress, and support cardiac function during recovery.
CoQ10 (Coenzyme Q10) is a mitochondrial antioxidant shown to improve patient health both pre- and post-operatively, particularly in cardiac surgery where mitochondrial function is critical. Life Extension's authoritative surgical recovery protocol, citing peer-reviewed research, lists CoQ10 with omega-3 fatty acids and vitamins C, D, and E as improving perioperative health.
CoQ10 is a fat-soluble mitochondrial electron carrier with a direct mechanistic link to post-viral fatigue. Research documents depleted CoQ10 in post-viral syndromes including ME/CFS and long COVID, with clinical trials showing supplementation reduces fatigue and pain in fibromyalgia and related post-viral fatigue conditions. A dedicated 2024 PMC review (PMC10779395) evaluated CoQ10's role in post-viral fatigue syndrome.
Coenzyme Q10 (CoQ10) has been studied for skin aging via topical and oral routes. A randomized trial of 33 patients found oral CoQ10 supplementation for 12 weeks significantly reduced periorbital wrinkles and improved skin smoothness versus placebo. Topical CoQ10 formulations reduce wrinkle depth by stabilizing mitochondrial function and exerting potent antioxidant effects in dermal cells.
CoQ10, in combination with other antioxidants, has been shown in one study to improve respiratory function in men with obstructive sleep apnea. OSA is characterized by oxidative stress from intermittent hypoxia, and CoQ10's established antioxidant and mitochondrial protective properties are mechanistically relevant. OSA patients are at elevated cardiovascular risk—a condition in which CoQ10 supplementation has demonstrated benefit.
Coenzyme Q10 (CoQ10) has been evaluated in meta-analyses for effects on lipid profiles including triglycerides. An umbrella review of meta-analyses (2024) found CoQ10 may have an effect on TG, though results are inconsistent. Strongest evidence is in populations with diabetes or metabolic disorders.
Sistemas corporales que coenzima Q10 (CoQ10) puede ayudar a apoyar.
Volver